

**2<sup>nd</sup> Cuneo City ImmunoTherapy Conference (CCITC)**

# **Immunotherapy in Hematological Malignancies 2021**

**CUNEO**  
**September 30,**  
**October 1-2, 2021**  
VARCO & AUDITORIUM  
FORO BOARIO



Organized by Massaia M., SC Ematologia AO S.Croce e Carle, Cuneo, Italy and  
Centro Interdipartimentale di Ricerca in Biologia Molecolare (CIRBM), Torino, Italy

## REQUESTED AUSPICES

AZIENDA OSPEDALIERA S. Croce e Carle - Cuneo

COMUNE DI CUNEO

PROVINCIA DI CUNEO

UNIVERSITÀ DI TORINO

FIL - Fondazione Italiana Linfomi

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo

SIE - Società Italiana di Ematologia

SIES - Società Italiana di Ematologia Sperimentale

<b>Fiorella</b>	<b>Altruda</b>	Turin - Italy
<b>Sergio</b>	<b>Amadori</b>	Rome - Italy
<b>Andrea</b>	<b>Bacigalupo</b>	Rome - Italy
<b>Mario</b>	<b>Boccardo</b>	Turin - Italy
<b>Chiara</b>	<b>Bonini</b>	Milan - Italy
<b>Ivan</b>	<b>Borrello</b>	Baltimore - USA
<b>Federico</b>	<b>Caligaris-Cappio</b>	Milan - Italy
<b>Carmelo</b>	<b>Carlo-Stella</b>	Milan - Italy
<b>Barbara</b>	<b>Castella</b>	Turin - Italy
<b>Roberto</b>	<b>Chiarle</b>	Boston - USA
<b>Fabio</b>	<b>Ciceri</b>	Milan - Italy
<b>Sandra</b>	<b>Demaria</b>	New York - USA
<b>Massimo</b>	<b>Di Nicola</b>	Milan - Italy
<b>Francesco</b>	<b>Di Raimondo</b>	Catania - Italy
<b>Gianpietro</b>	<b>Dotti</b>	Chapel Hill - USA
<b>Franca</b>	<b>Fagioli</b>	Turin - Italy
<b>Marina</b>	<b>Ferrarini</b>	Milan - Italy
<b>Robin</b>	<b>Foà</b>	Rome - Italy
<b>Ada</b>	<b>Funaro</b>	Turin - Italy
<b>Gianluca</b>	<b>Gaidano</b>	Novara - Italy
<b>Sara</b>	<b>Galimberti</b>	Pisa - Italy
<b>Filippo</b>	<b>Gherlinzoni</b>	Treviso - Italy
<b>Giorgio</b>	<b>Inghirami</b>	New York - USA
<b>Larry</b>	<b>Kwak</b>	Duarte - USA
<b>Marco</b>	<b>Ladetto</b>	Alessandria - Italy
<b>Roberto</b>	<b>Lemoli</b>	Genova - Italy
<b>Franco</b>	<b>Locatelli</b>	Rome - Italy
<b>Maurizio</b>	<b>Martelli</b>	Rome - Italy
<b>Giovanni</b>	<b>Martinelli</b>	Meldola (FC) - Italy
<b>Massimo</b>	<b>Massaia</b>	Cuneo, Turin - Italy
<b>Pellegrino</b>	<b>Musto</b>	Bari - Italy
<b>Pier Paolo</b>	<b>Pandolfi</b>	Harvard - USA
<b>Fabrizio</b>	<b>Pane</b>	Naples - Italy
<b>Cristina</b>	<b>Papayannidis</b>	Bologna - Italy
<b>Stefano</b>	<b>Persano</b>	Genova - Italy
<b>Antonello</b>	<b>Pinto</b>	Naples - Italy
<b>Pietro</b>	<b>Quaglino</b>	Turin - Italy
<b>Maria</b>	<b>Rescigno</b>	Milan - Italy
<b>Umberto</b>	<b>Ricardi</b>	Turin - Italy
<b>Chiara</b>	<b>Riganti</b>	Turin - Italy
<b>Marco</b>	<b>Ruella</b>	Philadelphia - USA
<b>Giuseppe</b>	<b>Saglio</b>	Turin - Italy
<b>Armando</b>	<b>Santoro</b>	Milan - Italy
<b>Elisa</b>	<b>Scarselli</b>	Rome - Italy
<b>Michele</b>	<b>Spina</b>	Aviano (PN) - Italy
<b>Pierfrancesco</b>	<b>Tassone</b>	Catanzaro - Italy
<b>Sarah</b>	<b>Tettamanti</b>	Monza - Italy
<b>Angelo</b>	<b>Vacca</b>	Bari - Italy
<b>Luca</b>	<b>Vago</b>	Milan - Italy
<b>Andrea</b>	<b>Velardi</b>	Perugia - Italy
<b>Umberto</b>	<b>Vitolo</b>	Candiolo (TO) - Italy

10:00 - 14:15 Registration

14:15 - 14:30 Welcome and information  
M. Massaia

## SESSION I

### Passive Immunotherapy: targeting tumor cells

M. Spina, U. Vitolo

14:30 - 14:50 Targeting B cells in lymphoma and chronic lymphocytic leukemia: groundwork & outlook  
G. Gaidano

14:50 - 15:10 Targeting tumor cells in T-cell acute lymphoblastic leukemia: groundwork & outlook  
P. Tassone

15:10 - 15:30 Targeting myeloid cells in acute leukemia: groundwork & outlook  
A. Funaro

15:30 - 15:50 Targeting tumor cells in cutaneous T-cell lymphomas  
P. Quaglino

15:50 - 16:00 Key Points  
M. Spina

16:00 - 16:30 *Coffee break*

## SESSION II

### Passive Immunotherapy: antibody-drug conjugates

M. Boccadoro, P. Musto

16:30 - 16:50 Brentuximab vedotin: Hodgkin lymphoma and beyond  
A. Pinto

16:50 - 17:10 Inotuzumab ozogamicin: pioneering therapeutic antibodies for acute lymphoblastic leukemia  
C. Papayannidis

17:10 - 17:30 Gemtuzumab ozogamicin: pioneering therapeutic antibodies for myeloid neoplasms  
F. Gherlinzoni

17:30 - 17:50 Polatuzumab vedotin: from diffuse large B-cell lymphoma to follicular lymphoma  
M. Martelli

17:50 - 18:00 Key points  
P. Musto

18:00 - 18:30 LECTURE  
Paradigm shifts in the diagnosis and treatment of acute myeloid leukemia  
S. Amadori, introduced by F. Pane

**SESSION III**

Tools & strategies to improve the efficacy of immunotherapy

F. Caligaris-Cappio, U. Ricardi

- 9:00 - 9:30 LECTURE  
Targeting the microbioma  
M. Rescigno, introduced by G. Martinelli
- 9:30 - 9:50 Cholesterol metabolism as a druggable intersection between cancer cells and immune-infiltrating cells  
C. Riganti
- 9:50 - 10:10 Inhibiting arginase and IDO in lympho-proliferative diseases  
F. Di Raimondo
- 10:10 - 10:30 In vitro 3D models to assess tumor-host interactions  
M. Ferrarini
- 10:30 - 10:50 Effects of radiation on tumor antigenicity and adjuvanticity  
S. Demaria
- 10:50 - 11:00 Key Points  
F. Caligaris-Cappio
- 11:00 - 11:30 *Coffee break*
- 11:30 - 12:00 LECTURE  
Deconstructing the molecular genetics of human cancer and its therapeutic implications  
P.P. Pandolfi, introduced by F. Altruda

**SESSION IV**

Passive Immunotherapy: targeting the tumor microenvironment

G. Martinelli, A. Vacca

- 12:00 - 12:20 PDI/PDL blockade in Hodgkin lymphoma and beyond  
A. Santoro
- 12:20 - 12:40 Mechanisms of resistance to immune checkpoint blockade  
B. Castella
- 12:40 - 13:00 Nanoparticles as delivery platforms to potentiate immune checkpoint blockade  
S. Persano
- 13:00 - 14:30 *Lunch*
- 14:30 - 15:00 LECTURE  
The tumor microenvironment in myeloma: a therapeutic opportunity or a major hurdle in the roadmap for a cure?  
A. Vacca, introduced by F. Caligaris-Cappio

**Immunotherapy  
in Hematological  
Malignancies 2021**

CUNEO  
September 30,  
October 1-2, 2021

## SESSION V

### Adoptive Immunotherapy: in vivo & ex vivo recruitment

R. Foà, R. Lemoli

- 15:00 - 15:20 Bispecific antibodies: from blinatumomab to the new generation  
[C. Carlo-Stella](#)
- 15:20 - 15:40 CAR-T for lymphoid malignancies: current challenges and novel approaches  
[M. Ruella](#)
- 15:40 - 16:00 NK effector mediated immunotherapies for the treatment of hemato-proliferative disorders  
[G. Inghirami](#)
- 16:00 - 16:30 *Coffee break*
- 16:30 - 16:50 CAR-T cells from bench to bedside  
[G. Dotti](#)
- 16:50 - 17:10 CAR-T therapy for acute myeloid leukemia: challenges and perspectives  
[S. Tettamanti](#)
- 17:10 - 17:30 New T-cell based immunotherapies and modelling CAR-T toxicity  
[C. Bonini](#)
- 17:30 - 17:50 Long-term safety follow-up of engineered immune cells  
[F. Ciceri](#)
- 17:50 - 18:00 Key points  
[R. Foà](#)

## SESSION VI

### Immune lessons from allo - HSCT

F. Fagioli, G. Saglio

- 9:00 - 9:20 Transplantation trends in Italy: outcome and complications  
[F. Ciceri](#)
- 9:20 - 9:40 The extra-value of uMRD in the allotransplant setting  
[S. Galimberti](#)
- 9:40 - 10:00 Changing paradigm for GvHD prophylaxis and leukemia relapse  
[A. Bacigalupo](#)
- 10:00 - 10:20 Immune manipulation to optimize the outcome of haploidentical transplants for acute leukemia  
[A. Velardi](#)
- 10:20 - 10:40 Immune mechanisms of leukemia escape after allogeneic transplantation  
[L. Vago](#)
- 10:40 - 11:00 Donor lymphocyte infusions (DLI) with T-Cells engineered with the iC9 suicide gene  
[F. Locatelli](#)
- 11:00 - 11:10 Key Points  
[F. Fagioli](#)
- 11:10 - 11:40 *Coffee break*

## SESSION VII

### Tumor vaccination: back to the future?

M. Di Nicola, M. Ladetto

- 11:40 - 12:10 LECTURE  
Active immune therapy in lymphoproliferative diseases:  
from idiotype vaccination to CAR-T cells  
L. Kwak, introduced by M. Massaia
- 12:10 - 12:30 ALK+lymphomas and beyond  
R. Chiarle
- 12:30 - 12:50 Targeting minimal residual disease (MRD) in myeloma  
with GVAX  
I. Borrello
- 12:50 - 13:10 Adenoviral vaccine targeting multiple neoantigens as  
strategy to eradicate large tumors combined with  
checkpoint blockade  
E. Scarselli
- 13:10 - 13:20 Key Points  
M. Di Nicola
- 13:20 - 13:30 Goodbyes and meeting close  
M. Massaia

## GENERAL INFORMATION

### Meeting Venue

Varco & Auditorium Foro Boario  
Via Carlo Pascal 5L - 12100 Cuneo, Italy

### Italian CME Credits

An Italian CME application has been submitted as follows:  
- Provider Studio ER Congressi SRL: ID 828-284173.  
- No. 14 CME credits for Physicians (disciplines: Hematology, Oncology, Internal Medicine, Clinical Pathology) and Biologists  
- Educational objective: "guidelines-protocols-procedures"

### Registration

Online registration: [www.ercongressi.it](http://www.ercongressi.it) - Congressi 2021  
The registration is free and includes: conference kit, access to the scientific sessions, attendance certificate, coffee breaks, lunch, slides of the Meeting

### Official Language

Italian

## SCIENTIFIC SECRETARIAT

### Prof. Massimo Massaia

SC Ematologia - AO S. Croce e Carle  
Via Michele Coppino 26, 12100 Cuneo, Italy  
Laboratorio di Immunologia dei Tumori del Sangue (LITS)  
Centro Interdipartimentale di Ricerca  
in Biologia Molecolare (CIRBM)  
Università degli Studi di Torino  
E-mail: [massimo.massaia@unito.it](mailto:massimo.massaia@unito.it)

## ORGANIZING SECRETARIAT

### Studio E.R. Congressi

Via Dè Poeti 1/7 - 40124 Bologna, Italy  
Phone +39 051 4210559  
Fax +39 051 4210174  
E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)  
[www.ercongressi.it](http://www.ercongressi.it)